Title: COMPOSITION FOR PREVENTING AND TREATMENT OF ASTHMA COMPRISING ALPHA-LIPOIC ACID AS AN EFFECTIVE COMPONENT

Abstract: The present invention relates to a composition for the prevention and treatment of asthma, which contains α-lipoic acid as an active ingredient. The inventive composition reduces not only airway hyperreactivity, a typical symptom of asthma, but also inflammation occurring in asthma. Accordingly, the inventive composition will be useful for the prevention and treatment of asthma.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report: 3 February 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC7 A61K 31/385, A61P 11/06
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7 A61K 31/385, A61P 11/06

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean patents and applications for inventions since 1975

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN [Medline, Biosis, Embase, (lipoic acid? or dihydroliopolic acid?) and (asthma or antiinflamma? or immunoglobulin E)]

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 5569670 A (ASTA MEDICA AKTINGESELLSHAFT) 29 October 1996 See abstract and column 11, lines 3-4.</td>
<td>1 - 7</td>
</tr>
<tr>
<td>X</td>
<td>US 5728735 A (ASTA PHARMA AKTINGESELLSHAFT) 17 March 1998 See abstract.</td>
<td>1 - 7</td>
</tr>
<tr>
<td>X</td>
<td>EGAN et al., 'Radical scavenging as the mechanism for stimulation of prostaglandin cyclooxygenase and depression of inflammation by lipoic acid and sodium iodide', Prostaglandins, December 1978, Vol.16, No.6, pp.861-869 See the whole document.</td>
<td>1 - 7</td>
</tr>
<tr>
<td>A</td>
<td>JAVOR et al., 'Cytoprotective effect of free radical scavengers against macular damage produced by different antiinflammatory drugs', International Journal of Tissue Reactions, 1986, Vol.8(01), pp.35-40 See the whole document.</td>
<td>1 - 7</td>
</tr>
</tbody>
</table>

☐ Further documents are listed in the continuation of Box C.  X See patent family annex.

* Special categories of cited documents:
  *A* document defining the general state of the art which is not considered to be of particular relevance
  *E* earlier application or patent but published on or after the international filing date
  *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)
  *O* document referring to an oral disclosure, use, exhibition or other means
  *P* document published prior to the international filing date but later than the priority date claimed

  "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  "&" document member of the same patent family

Date of the actual completion of the international search
11 AUGUST 2004 (11.08.2004)

Date of mailing of the international search report
12 AUGUST 2004 (12.08.2004)

Name and mailing address of the ISA/KR
Korean Intellectual Property Office
920 Dusan-dong, Seo-gu, Daejeon 302-701, Republic of Korea

Authorized officer
LEE, Mi Jeong

Telephone No. 82-42-481-5601

Form PCT/ISA/210 (second sheet) (January 2004)
# INTERNATIONAL SEARCH REPORT

Information on patent family members

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>US5728735A</td>
<td>17.03.1998</td>
<td>US6271254B1, US5334612A, JP3169813A2, IT9048456A0, GB822979B</td>
<td>07.08.2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FR2653997B1, EP0812500A2, EP0427247A2, DE4035442A1, CH0684054A</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>BE1003334A, CA2029506AA, AT0128053E, ES0508501C2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE4002706A1, CA2009593AA, AU062227682</td>
<td></td>
</tr>
</tbody>
</table>

Form PCT/ISA/210 (patent family annex) (January 2004)